Medicine and Dentistry
Hepatectomy
100%
Surgery
79%
Colorectal Liver Metastasis
64%
Overall Survival
41%
Pancreaticoduodenectomy
38%
Pancreas Adenocarcinoma
33%
Cancer Surgery
32%
Pancreatectomy
27%
Recurrent Disease
24%
Hazard Ratio
23%
Circulating Tumor DNA
23%
Morphine
23%
Neoplasm
22%
Liver Metastasis
21%
Neoadjuvant Therapy
20%
Malignant Neoplasm
19%
Surgical Oncology
19%
Recurrence Free Survival
17%
Colorectal Carcinoma
16%
Pancreas Fistula
16%
Retroperitoneal Lymph Node Dissection
15%
Surgeon
15%
Pancreas Cancer
15%
Hepatocellular Carcinoma
15%
Diseases
13%
Gallbladder Cancer
13%
Primary Tumor
12%
Abdominal Cancer
12%
Cholangiocarcinoma
12%
Care Pathway
11%
Trametinib
11%
Embolization
11%
Hepatic Portal Vein
11%
Health Care Cost
10%
Minimally Invasive Procedure
9%
Distal Pancreatectomy
9%
Biological Marker
9%
Lymph Node
9%
Koji
8%
Odds Ratio
8%
Clinical Pathway
8%
Hepatic Vein
8%
Tertiary Care
8%
Postoperative Complication
7%
MEK Inhibitor
7%
Neoadjuvant Chemotherapy
7%
Programmed Death-Ligand 1
7%
Xenograft
7%
Metastatic Colorectal Cancer
7%
CA 19-9 Antigen
7%
Keyphrases
Colorectal Liver Metastases
56%
Hepatectomy
46%
Resection
33%
Overall Survival
32%
Hazard Ratio
24%
Pancreaticoduodenectomy
24%
Risk Stratification
24%
Circulating Tumor DNA (ctDNA)
23%
Pancreatic Adenocarcinoma
20%
Recurrence-free Survival
19%
Neoadjuvant Therapy
18%
Pancreatectomy
16%
Gallbladder Cancer
12%
High Risk
12%
Confidence Interval
12%
Colorectal Cancer
12%
Carbohydrate Antigen 19-9 (CA19-9)
11%
Cancer Surgery
11%
Pancreatic Cancer
11%
Hepatocellular Carcinoma
11%
Portal Vein Embolization
11%
Pancreatic Ductal Adenocarcinoma
10%
Lymphadenectomy
10%
Oncological Outcomes
9%
Tumor Protein p53 (TP53)
9%
Intrahepatic Cholangiocarcinoma (iCCA)
9%
Post-hepatectomy
8%
Synchronous Liver Metastases
8%
Future Liver Remnant
8%
Liver
8%
Pathologic
8%
Oral Morphine Equivalent
8%
Opioid Use
8%
Postoperative Pancreatic Fistula
8%
Metastases Resection
8%
Clinical Pathway
8%
Pathological Response
8%
Gastric Cancer
7%
Readmission
7%
Surgery First
7%
Length of Stay
7%
Early Recurrence
7%
Neoadjuvant Chemotherapy
7%
Hepatic Resection
7%
MEK Inhibitor (MEKi)
7%
Fusion Protein
7%
Trametinib
7%
Metastatic Colorectal Cancer (mCRC)
7%
Primary Tumor Resection
7%
Accelerated Discharge
7%